TY - JOUR
T1 - Identification of sex-specific biomarkers predicting new-onset heart failure
AU - Raafs, Anne
AU - Verdonschot, Job
AU - Ferreira, João Pedro
AU - Wang, Ping
AU - Collier, Timothy
AU - Henkens, Michiel
AU - Björkman, Jens
AU - Boccanelli, Alessandro
AU - Clark, Andrew L.
AU - Delles, Christian
AU - Diez, Javier
AU - González, Arantxa
AU - Girerd, Nicolas
AU - Jukema, J. Wouter
AU - Pinet, Florence
AU - Rossignol, Patrick
AU - Thum, Thomas
AU - Vodovar, Nicolas
AU - de Boer, Rudolf A.
AU - van Empel, Vanessa
AU - Staessen, Jan A.
AU - Hazebroek, Mark
AU - Cleland, John
AU - Zannad, Faiez
AU - Heymans, Stephane
N1 - Publisher Copyright:
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2021/10
Y1 - 2021/10
N2 - Aims: Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex-specifically are scarce. This study therefore aims to test the sex-specificity of 252 protein biomarkers for new-onset HF. Methods and results: A matched case–control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new-onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH-ABC, & PROSPER), follow-up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O-link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex-specificity (P < 0.013). E-selectin and interleukin 1 receptor antagonist were more female-specific, whereas IL17A and CHIT1 tended to be male sex-specific for incident HF. Conclusions: The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline.
AB - Aims: Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex-specifically are scarce. This study therefore aims to test the sex-specificity of 252 protein biomarkers for new-onset HF. Methods and results: A matched case–control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new-onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH-ABC, & PROSPER), follow-up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O-link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex-specificity (P < 0.013). E-selectin and interleukin 1 receptor antagonist were more female-specific, whereas IL17A and CHIT1 tended to be male sex-specific for incident HF. Conclusions: The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline.
UR - http://www.scopus.com/inward/record.url?scp=85108287742&partnerID=8YFLogxK
U2 - 10.1002/ehf2.13476
DO - 10.1002/ehf2.13476
M3 - Article
C2 - 34156155
AN - SCOPUS:85108287742
SN - 2055-5822
VL - 8
SP - 3512
EP - 3520
JO - ESC heart failure
JF - ESC heart failure
IS - 5
ER -